IGF-methotrexate conjugate - IGF Oncology

Drug Profile

IGF-methotrexate conjugate - IGF Oncology

Alternative Names: 765-IGF-MTX; IGF-methotrexate conjugate

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator IGF Oncology
  • Developer IGF Oncology; University of Chicago
  • Class Antineoplastics; Benzamides; Drug conjugates; Glutamates; Growth factors; Peptides; Pterins; Small molecules; Somatomedins
  • Mechanism of Action Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Dec 2013 Phase-I clinical trials in Solid tumours (second-line therapy of greater, late-stage disease) in USA (IV)
  • 22 May 2009 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top